Norgestrel clinical trials
How each study uses Norgestrel is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 16 Apr 1968 · OVRAL · NDA 016672 (FDA, Drugs@FDA; in a combination)
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2018 (2)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2018 | 2 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 1
HRA Pharma (3) · National Cancer Institute (NCI) (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- Levonorgestrel is one of its enantiomers, counted on its own page source
Studies
Open first, then newest update. How each study uses Norgestrel is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Adherence With Continuous-dose Oral Contraceptive: Evaluation of Self-Selection and UseCompletedPhase 3HRA PharmaNCT04112095Written as Norgestrel 0.075 mg tablets
- A Study of Oral Contraception Under Simulated OTC ConditionsTerminatedPhase 3HRA PharmaNCT03559010Written as Norgestrel 0.075 mg tablets
- Effect of Norgestrel 75 mcg on Cervical Mucus and Ovarian Activity During Perfect Use, After One Delayed Intake and After a Missed PillCompletedPhase 2HRA PharmaNCT03585712Written as Norgestrel 0.075 mg
- Hormone Therapy in Preventing Endometrial Cancer in Patients With a Genetic Risk For Hereditary Nonpolyposis Colon CancerCompletedPhase 2National Cancer Institute (NCI)NCT00033358Written as norgestrel
Codes
What other systems call Norgestrel · ClinicalTrials.gg INT007910
- MeSH (NLM) D009644NorgestrelConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 3J8Q1747Z2NORGESTRELConfirmed FDA, NLM, Wikidata
- Wikidata Q7051185norgestrelConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C703NorgestrelOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D009644 | Norgestrel | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 3J8Q1747Z2 | NORGESTREL | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q7051185 | norgestrel | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C703 | Norgestrel | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.